mTOR Inhibition Induces Compensatory, Therapeutically Targetable MEK Activation in Renal Cell Carcinoma

Rapamycin derivatives allosterically targeting mTOR are currently FDA approved to treat advanced renal cell carcinoma (RCC), and catalytic inhibitors of mTOR/PI3K are now in clinical trials for treating various solid tumors. We sought to investigate the relative efficacy of allosteric versus catalyt...

Descripción completa

Detalles Bibliográficos
Autores principales: Bailey, Sean T., Zhou, Bing, Damrauer, Jeffrey S., Krishnan, Bhavani, Wilson, Harper L., Smith, Aleisha M., Li, Mingqing, Yeh, Jen Jen, Kim, William Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4152178/
https://www.ncbi.nlm.nih.gov/pubmed/25180793
http://dx.doi.org/10.1371/journal.pone.0104413

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4152178/
https://www.ncbi.nlm.nih.gov/pubmed/25180793
http://dx.doi.org/10.1371/journal.pone.0104413

Ejemplares similares